ArticlePloS one2012
MicroRNA expression profiles of whole blood in lung adenocarcinoma.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Current situation and trend of non-coding RNA in rheumatoid arthritis: a review and bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses.Respiratory research · 2020Pooled it
- Trial
- Circulating miR-107, miR-199, and miR-485 Have High Diagnostic Potential in Non-small Cell Lung Cancer: An Exploratory Study.Clinical Medicine Insights. Oncology · 2026Article
- In Silico Identification of Dysregulated miRNAs TargetingDiseases (Basel, Switzerland) · 2024Article
- A two-miRNA signature (miR-21 and miR-92) in peripheral whole blood as a potential biomarker for diagnosis of human cerebral aneurysms.Archives of medical science : AMS · 2024Article
- Plasma microRNA Profiling in Type 2 Diabetes Mellitus: A Pilot Study.International journal of molecular sciences · 2023Article
- Diagnostic applications and therapeutic option of Cascade CRISPR/Cas in the modulation of miRNA in diverse cancers: promises and obstacles.Journal of cancer research and clinical oncology · 2023Review
- MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2023Review
- Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.Frontiers in oncology · 2023Review
- A panel of blood-derived miRNAs with a stable expression pattern as a potential pan-cancer detection signature.Frontiers in molecular biosciences · 2022Article
- Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer.Oncology letters · 2021Article
- Identification of a Potentially Functional microRNA-mRNA Regulatory Network in Lung Adenocarcinoma Using a Bioinformatics Analysis.Frontiers in cell and developmental biology · 2021Article
- Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer.PeerJ · 2021Article
- Microarray Expression Profile and Analysis of Circular RNA Regulatory Network in Pulmonary Thromboembolism.International journal of general medicine · 2021Article
- A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.Journal of clinical laboratory analysis · 2020Article
- In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor.PLoS genetics · 2020Article
- Temporally Altered miRNA Expression in a Piglet Model of Hypoxic Ischemic Brain Injury.Molecular neurobiology · 2020Article
- A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy.Communications biology · 2020Article
- Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The association of lung cancer with changes in microRNAs in plasma shown in multiple studies suggests a utility for circulating microRNA biomarkers in non-invasive detection of the disease. We examined if presence of lung cancer is reflected in whole blood microRNA expression as well, possibly because of a systemic response. Locked nucleic acid microarrays were used to quantify the global expression of microRNAs in whole blood of 22 patients with lung adenocarcinoma and 23 controls, ten of whom had a radiographically detected non-cancerous lung nodule and the other 13 were at high risk for developing lung cancer because of a smoking history of >20 pack-years. Cases and controls differed significantly for age with a mean difference of 10.7 years, but not for gender, race, smoking history, blood hemoglobin, platelet count, or white blood cell count. Of 1282 quantified human microRNAs, 395 (31%) were identified as expressed in the study's subjects, with 96 (24%) differentially expressed between cases and controls. Classification analyses of microRNA expression data were performed using linear kernel support vector machines (SVM) and top-scoring pairs (TSP) methods, and classifiers to identify presence of lung adenocarcinoma were internally cross-validated. In leave-one-out cross-validation, the TSP classifiers had sensitivity and specificity of 91% and 100%, respectively. The values with SVM were both 91%. In a Monte Carlo cross-validation, average sensitivity and specificity values were 86% and 97%, respectively, with TSP, and 88% and 89%, respectively, with SVM. MicroRNAs miR-190b, miR-630, miR-942, and miR-1284 were the most frequent constituents of the classifiers generated during the analyses. These results suggest that whole blood microRNA expression profiles can be used to distinguish lung cancer cases from clinically relevant controls. Further studies are needed to validate this observation, including in non-adenocarcinomatous lung cancers, and to clarify upon the confounding effect of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.